News for Healthier Living

Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies

A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies--including ovarian and uterine cancers--found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

April 20, 2026


April 20 2026

April 19 2026

April 18 2026

April 17 2026

April 16 2026

April 15 2026

April 14 2026

April 13 2026

April 12 2026

April 11 2026

April 10 2026

April 9 2026

April 8 2026

April 7 2026

April 6 2026